Robert F. Kennedy Jr., President Donald Trump's nominee to be secretary of the Health and Human Services Department, testifies in front of the Senate Finance Committee on January 29, 2025.
RFK Jr Pressed on Whether He and Trump Will 'Cave to Big Pharma' on Medicare Drug Prices
"Will you defend the law in the Inflation Reduction Act which already is negotiating prescription drug prices?" Sen. Bernie Sanders asked Kennedy during his second confirmation hearing.
Senate Democrats and Independent Sen. Bernie Sanders on Thursday pressed Robert F. Kennedy Jr., President Donald Trump's pick to lead the Health and Human Services Department, to pledge that the new administration won't give in to the pharmaceutical industry's attacks on a popular Medicare drug price negotiation program that has already yielded significant results.
Sanders raised the matter during Kennedy's confirmation hearing before the Senate Health, Education, Labor, and Pensions Committee, on which the Vermont senator serves as the ranking member.
"Will you defend the law in the Inflation Reduction Act which already is negotiating prescription drug prices?" Sanders asked, referring to the Biden-era measure that empowered Medicare to negotiate the prices of a select number of prescription drugs directly with pharmaceutical companies.
Declining to provide a yes or no answer to Sanders' question, Kennedy replied that "President Trump wants us to negotiate drug prices" and added that, if confirmed as Health and Human Services (HHS) secretary, he would "comply with the laws."
Watch:
The exchange came after the Centers for Medicare and Medicaid Services (CMS), an agency within HHS, issued a statement Wednesday declaring that "lowering the cost of prescription drugs for Americans is a top priority of President Trump and his administration" and expressing commitment to "incorporating lessons learned to date from the [Inflation Reduction Act] program and to considering opportunities to bring greater transparency in the negotiation program."
"CMS intends to provide opportunities for stakeholders to provide specific ideas to improve the negotiation program, consistent with the goals of achieving greater value for beneficiaries and taxpayers and continuing to foster innovation," the agency added.
While some advocates for lower drug prices cautiously welcomed the CMS statement, Senate Democrats warned Thursday that its choice of language "appeared to open the door to Big Pharma's requests."
"If confirmed as secretary, you will be under tremendous pressure to cave to Big Pharma and undermine Medicare drug price negotiation Republicans have worked in lock-step with Big Pharma by relentlessly attacking Medicare drug price negotiation at every turn," a group of 12 Senate Democrats and Sanders wrote in a letter to Kennedy. "Now, Republicans have unified control of the federal government. They will undoubtedly try to leverage this power to walk back the progress Democrats made to lower drug prices through this important new authority."
The letter pushes Kennedy to answer a number of questions related to the drug price negotiation program, including whether he would recommend that the Trump administration defend the program from the pharmaceutical industry's ongoing legal assault.
"On behalf of the tens of millions of Americans who count on Medicare," the new letter states, "Democrats on the Senate Finance Committee want to know whether the Trump administration will follow through on negotiating with Big Pharma to deliver the lower costs promised to the American people."
After Trump announced his intent to nominate Kennedy as HHS chief late last year, the pharmaceutical lobby made clear its plan to push the new administration to undercut the price negotiation program that is poised to deliver billions of dollars in savings by bringing down the prices of expensive and widely used medications.
Earlier this month, the CEO of pharmaceutical giant Eli Lilly said his company and other drugmakers would ask the Trump administration to pause the price-negotiation program, claiming that "they need to fix it" before proceeding to talks over the next slate of 15 drugs selected in the final days of the Biden administration.
In their letter on Thursday, the senators demanded that Kennedy "confirm in writing" that he "will follow the law and reject
Big Pharma's request to pause Medicare drug price negotiation."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, The U.S. is on a fast track to authoritarianism like nothing I've ever seen. Meanwhile, corporate news outlets are utterly capitulating to Trump, twisting their coverage to avoid drawing his ire while lining up to stuff cash in his pockets. That's why I believe that Common Dreams is doing the best and most consequential reporting that we've ever done. Our small but mighty team is a progressive reporting powerhouse, covering the news every day that the corporate media never will. Our mission has always been simple: To inform. To inspire. And to ignite change for the common good. Now here's the key piece that I want all our readers to understand: None of this would be possible without your financial support. That's not just some fundraising cliche. It's the absolute and literal truth. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. The final deadline for our crucial Summer Campaign fundraising drive is just days away, and we’re falling short of our must-hit goal. Will you donate now to help power the nonprofit, independent reporting of Common Dreams? Thank you for being a vital member of our community. Together, we can keep independent journalism alive when it’s needed most. - Craig Brown, Co-founder |
Senate Democrats and Independent Sen. Bernie Sanders on Thursday pressed Robert F. Kennedy Jr., President Donald Trump's pick to lead the Health and Human Services Department, to pledge that the new administration won't give in to the pharmaceutical industry's attacks on a popular Medicare drug price negotiation program that has already yielded significant results.
Sanders raised the matter during Kennedy's confirmation hearing before the Senate Health, Education, Labor, and Pensions Committee, on which the Vermont senator serves as the ranking member.
"Will you defend the law in the Inflation Reduction Act which already is negotiating prescription drug prices?" Sanders asked, referring to the Biden-era measure that empowered Medicare to negotiate the prices of a select number of prescription drugs directly with pharmaceutical companies.
Declining to provide a yes or no answer to Sanders' question, Kennedy replied that "President Trump wants us to negotiate drug prices" and added that, if confirmed as Health and Human Services (HHS) secretary, he would "comply with the laws."
Watch:
The exchange came after the Centers for Medicare and Medicaid Services (CMS), an agency within HHS, issued a statement Wednesday declaring that "lowering the cost of prescription drugs for Americans is a top priority of President Trump and his administration" and expressing commitment to "incorporating lessons learned to date from the [Inflation Reduction Act] program and to considering opportunities to bring greater transparency in the negotiation program."
"CMS intends to provide opportunities for stakeholders to provide specific ideas to improve the negotiation program, consistent with the goals of achieving greater value for beneficiaries and taxpayers and continuing to foster innovation," the agency added.
While some advocates for lower drug prices cautiously welcomed the CMS statement, Senate Democrats warned Thursday that its choice of language "appeared to open the door to Big Pharma's requests."
"If confirmed as secretary, you will be under tremendous pressure to cave to Big Pharma and undermine Medicare drug price negotiation Republicans have worked in lock-step with Big Pharma by relentlessly attacking Medicare drug price negotiation at every turn," a group of 12 Senate Democrats and Sanders wrote in a letter to Kennedy. "Now, Republicans have unified control of the federal government. They will undoubtedly try to leverage this power to walk back the progress Democrats made to lower drug prices through this important new authority."
The letter pushes Kennedy to answer a number of questions related to the drug price negotiation program, including whether he would recommend that the Trump administration defend the program from the pharmaceutical industry's ongoing legal assault.
"On behalf of the tens of millions of Americans who count on Medicare," the new letter states, "Democrats on the Senate Finance Committee want to know whether the Trump administration will follow through on negotiating with Big Pharma to deliver the lower costs promised to the American people."
After Trump announced his intent to nominate Kennedy as HHS chief late last year, the pharmaceutical lobby made clear its plan to push the new administration to undercut the price negotiation program that is poised to deliver billions of dollars in savings by bringing down the prices of expensive and widely used medications.
Earlier this month, the CEO of pharmaceutical giant Eli Lilly said his company and other drugmakers would ask the Trump administration to pause the price-negotiation program, claiming that "they need to fix it" before proceeding to talks over the next slate of 15 drugs selected in the final days of the Biden administration.
In their letter on Thursday, the senators demanded that Kennedy "confirm in writing" that he "will follow the law and reject
Big Pharma's request to pause Medicare drug price negotiation."
Senate Democrats and Independent Sen. Bernie Sanders on Thursday pressed Robert F. Kennedy Jr., President Donald Trump's pick to lead the Health and Human Services Department, to pledge that the new administration won't give in to the pharmaceutical industry's attacks on a popular Medicare drug price negotiation program that has already yielded significant results.
Sanders raised the matter during Kennedy's confirmation hearing before the Senate Health, Education, Labor, and Pensions Committee, on which the Vermont senator serves as the ranking member.
"Will you defend the law in the Inflation Reduction Act which already is negotiating prescription drug prices?" Sanders asked, referring to the Biden-era measure that empowered Medicare to negotiate the prices of a select number of prescription drugs directly with pharmaceutical companies.
Declining to provide a yes or no answer to Sanders' question, Kennedy replied that "President Trump wants us to negotiate drug prices" and added that, if confirmed as Health and Human Services (HHS) secretary, he would "comply with the laws."
Watch:
The exchange came after the Centers for Medicare and Medicaid Services (CMS), an agency within HHS, issued a statement Wednesday declaring that "lowering the cost of prescription drugs for Americans is a top priority of President Trump and his administration" and expressing commitment to "incorporating lessons learned to date from the [Inflation Reduction Act] program and to considering opportunities to bring greater transparency in the negotiation program."
"CMS intends to provide opportunities for stakeholders to provide specific ideas to improve the negotiation program, consistent with the goals of achieving greater value for beneficiaries and taxpayers and continuing to foster innovation," the agency added.
While some advocates for lower drug prices cautiously welcomed the CMS statement, Senate Democrats warned Thursday that its choice of language "appeared to open the door to Big Pharma's requests."
"If confirmed as secretary, you will be under tremendous pressure to cave to Big Pharma and undermine Medicare drug price negotiation Republicans have worked in lock-step with Big Pharma by relentlessly attacking Medicare drug price negotiation at every turn," a group of 12 Senate Democrats and Sanders wrote in a letter to Kennedy. "Now, Republicans have unified control of the federal government. They will undoubtedly try to leverage this power to walk back the progress Democrats made to lower drug prices through this important new authority."
The letter pushes Kennedy to answer a number of questions related to the drug price negotiation program, including whether he would recommend that the Trump administration defend the program from the pharmaceutical industry's ongoing legal assault.
"On behalf of the tens of millions of Americans who count on Medicare," the new letter states, "Democrats on the Senate Finance Committee want to know whether the Trump administration will follow through on negotiating with Big Pharma to deliver the lower costs promised to the American people."
After Trump announced his intent to nominate Kennedy as HHS chief late last year, the pharmaceutical lobby made clear its plan to push the new administration to undercut the price negotiation program that is poised to deliver billions of dollars in savings by bringing down the prices of expensive and widely used medications.
Earlier this month, the CEO of pharmaceutical giant Eli Lilly said his company and other drugmakers would ask the Trump administration to pause the price-negotiation program, claiming that "they need to fix it" before proceeding to talks over the next slate of 15 drugs selected in the final days of the Biden administration.
In their letter on Thursday, the senators demanded that Kennedy "confirm in writing" that he "will follow the law and reject
Big Pharma's request to pause Medicare drug price negotiation."